Outcomes in patients with invasive candidiasis treated with anidulafungin or fluconazole: Comparison of response to treatment in ICU patients and/or patients with end-organ dysfunction

被引:0
|
作者
Shorr, Andrew F. [1 ]
Kett, Dan H. [2 ]
Sanchez, Sonia [3 ]
Gasper, Sabina [3 ]
Schlamm, Haran T. [3 ]
机构
[1] Washington Hosp Ctr, Washington, DC 20010 USA
[2] Univ Miami, Miami, FL 33152 USA
[3] Pfizer Inc, New York, NY USA
关键词
D O I
暂无
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
899
引用
收藏
页码:A250 / A250
页数:1
相关论文
共 50 条
  • [1] Anidulafungin in the treatment of patients with invasive candidiasis
    Kett, Daniel H.
    Cubillos, G. Fernando
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 : S99 - S102
  • [2] Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients
    M Ruhnke
    J Paiva
    W Meersseman
    J Pachl
    I Grigoras
    G Sganga
    F Menichetti
    P Montravers
    G Auzinger
    G Dimopoulos
    M Borges Sá
    P Miller
    T Marček
    M Kantecki
    Critical Care, 15 (Suppl 1):
  • [3] SEPSIS PATIENTS WITHOUT END-ORGAN DYSFUNCTION STILL BENEFIT FROM ICU ADMISSION
    Stark, Thomas
    Rhee, Daniel
    Purtill, Mary-Anne
    Nieman, Wendy
    Posa, Patricia
    Brandt, Mary-Margaret
    Bander, Joseph
    Anderson, Harry
    Wahl, Wendy
    CRITICAL CARE MEDICINE, 2012, 40 (12) : U288 - U289
  • [4] Intraabdominal candidiasis in surgical ICU patients treated with anidulafungin: A multicenter retrospective study
    Maseda, Emilio
    Rodriguez-Manzaneque, Marta
    Dominguez, David
    Gonzalez-Serrano, Matilde
    Mouriz, Lorena
    Alvarez-Escudero, Julian
    Ojeda, Nazario
    Sanchez-Zamora, Purificacion
    Granizo, Juan-Jose
    Gimenez, Maria-Jose
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2016, 29 (01) : 32 - 39
  • [5] Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients
    Ruhnke, M.
    Paiva, J. A.
    Meersseman, W.
    Pachl, J.
    Grigoras, I.
    Sganga, G.
    Menichetti, F.
    Montravers, P.
    Auzinger, G.
    Dimopoulos, G.
    Borges Sa, M.
    Miller, P. J.
    Marcek, T.
    Kantecki, M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (07) : 680 - 687
  • [6] Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
    Daniel H Kett
    Andrew F Shorr
    Annette C Reboli
    Arlene L Reisman
    Pinaki Biswas
    Haran T Schlamm
    Critical Care, 15
  • [7] Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
    Kett, Daniel H.
    Shorr, Andrew F.
    Reboli, Annette C.
    Reisman, Arlene L.
    Biswas, Pinaki
    Schlamm, Haran T.
    CRITICAL CARE, 2011, 15 (05):
  • [8] Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis Focus on Critically Ill Patients
    Reboli, Annette C.
    Rotstein, Coleman
    Kett, Daniel H.
    Maschio, Michael
    Cartier, Shannon
    Chambers, Richard
    Tarallo, Miriam
    PHARMACOECONOMICS, 2011, 29 (08) : 705 - 717
  • [9] Erectile Dysfunction: Indicator of End-Organ Damage in Cardiovascular Patients
    Baumhaekel, Magnus
    Schlimmer, Nils
    Kratz, Mario T.
    Boehm, Michael
    MEDIZINISCHE KLINIK, 2009, 104 (04) : 309 - 313
  • [10] PHARMACOECONOMIC ANALYSIS OF ANIDULAFUNGIN, MICAFUNGIN, CASPOFUNGIN AND FLUCONAZOLE IN THE TREATMENT OF CANDIDEMIA AND/OR INVASIVE CANDIDIASIS IN NON-NEUTROPENIC ADULT PATIENTS IN SPAIN
    Grau, S.
    Pozo, J.
    Roma, E.
    Salavert, M.
    Barrueta, J.
    Peral, C.
    Rodriguez, I
    Rubio-Rodriguez, D.
    Rubio-Terres, C.
    VALUE IN HEALTH, 2015, 18 (07) : A584 - A585